Press Releases
 
Antidiabetics Market to Incur Rapid Extension During 2015 - 2023

, 17 April 2019 -- Antidiabetics Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2015 - 2023

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose).

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine. Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk’s diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population.

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=8809

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

# # #


Submitted by hawer on Wednesday, 17 April 2019 at 10:02 PM
Category: Health Care & Medical
 
Related News

Coronary Stents Market: Increase in Geriatric Population to Drive Demand
Friday, 19 Apr 2019

Wearable Medical Devices Market - Rising Number of Sports and Fitness Enthusiasts to Boost the Deman
Friday, 19 Apr 2019

Catheters Market - Increasing Demand for Minimally Invasive Surgeries to Spur the Demand
Friday, 19 Apr 2019

Fragment-based Drug Discovery Market Will be Worth US$1.15 bn by 2023
Friday, 19 Apr 2019

Homeopathy Product Market is Projected to be Worth US$17,486.2 mn by 2024
Friday, 19 Apr 2019

Related Events

3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
Monday, 22 Apr 2019

Rx Drug Abuse and Heroin Summit
Monday, 22 Apr 2019

European NeoAg Summit 2019
Tuesday, 23 Apr 2019

MASS East
Wednesday, 24 Apr 2019

8th Digital Marketing for Medical Devices West
Wednesday, 24 Apr 2019

Latest News

Four Years of Despair Book Launch
Sunday, 21 Apr 2019

ΑΠΟΦΡΑΞΕΙΣ ΑΘΗΝΑ Α&#
Sunday, 21 Apr 2019

Infographic presenting the 6 Steps to Sell a House in Wisconsin
Sunday, 21 Apr 2019

Benefits of the Amazing Red Tea for Weight Loss in the Healthiest Way
Sunday, 21 Apr 2019

Caviar Benefits for your Health
Sunday, 21 Apr 2019

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Sunday, 21 April 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Palo Alto Networks: Palo Alto Networks Next Generation Firewall Hands-on Seminar
  • DOZ Live Inspirational Conference (DOZ Live)
  • 3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
  • Rx Drug Abuse and Heroin Summit
  • European NeoAg Summit 2019

  • Latest Jobs
    Sorry, there are currently no entries posted here.